Skip to main content
HR 7474 117th Congress House Health Administrative law and regulatory procedures Department of Health and Human Services Government information and archives Manufacturing Medical research Prescription drugs Research and development

Pharmaceutical Research Transparency Act of 2022

Introduced: April 7, 2022 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 8, 2022
Referred to the Subcommittee on Health.
Apr 7, 2022
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 7, 2022
Introduced in House
 Plain-English summary Congressional Research Service

Pharmaceutical Research Transparency Act of 2022

This bill requires the disclosure of costs associated with clinical trials and pharmaceutical research and development.

Specifically, the National Institutes of Health must create a publicly available repository of cost data from certain clinical trials that test the efficacy of drugs, biological products, and devices in human subjects. For each applicable trial, the registry must, among other information, include the total and per patient cost of the trial, as well as costs for personnel, health care services, and other categories of expenditures. Information must be added to the registry within one year of the trial's completion.

The bill also requires drug manufacturers to include their research and development expenditures for drugs and biological products in annual disclosures made to the Securities and Exchange Commission.

What's happening now April 8, 2022

Referred to the Subcommittee on Health.

 Committees of jurisdiction 3
 Cosponsors 11
All 11 Democratic 11